Exceptionally Long Recurrence‐Free Survival in a Male Patient With Fibrolamellar Hepatocellular Carcinoma
Abstract
Fibrolamellar hepatocellular carcinoma (FLHCC) accounts for less than 1% of all primary liver cancers. Due to an absence of known risk factors, most individuals are diagnosed at advanced stages of disease. Subsequently, these tumors carry a 30%-50% mortality rate and a 33%-100% recurrence rate in those treated with curative intent. Here, we describe an incidental discovery of an FLHCC tumor in a young male patient, who following surgical resection has remained recurrence free for over 11 years. This exceptionally long recurrence-free survival highlights the advantage of early-stage detection, the benefit of complete tumor resection, and further underscores the importance of regular postresection cancer surveillance.
Fields of Study & Subjects
Hepatocellular Carcinoma Treatment and Prognosis
Hepatitis B Virus Studies
Liver physiology and pathology
Publication details
- Journal / source
- Case Reports in Hepatology
- Volume
- 2026
- Issue
- 1
- Pages
- 7445319–7445319
- Publication date
- 1 January 2026
- Language
- EN